Boston Scientific Co. (NYSE:BSX) Shares Purchased by Kentucky Retirement Systems Insurance Trust Fund

Kentucky Retirement Systems Insurance Trust Fund boosted its position in shares of Boston Scientific Co. (NYSE:BSX) by 8.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,284 shares of the medical equipment provider’s stock after buying an additional 3,683 shares during the period. Kentucky Retirement Systems Insurance Trust Fund’s holdings in Boston Scientific were worth $4,223,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Kestra Investment Management LLC purchased a new stake in Boston Scientific in the 4th quarter valued at $49,000. Atria Wealth Solutions Inc. boosted its stake in shares of Boston Scientific by 56.5% during the fourth quarter. Atria Wealth Solutions Inc. now owns 17,965 shares of the medical equipment provider’s stock worth $1,605,000 after buying an additional 6,487 shares during the period. Venturi Wealth Management LLC grew its holdings in shares of Boston Scientific by 323.6% during the fourth quarter. Venturi Wealth Management LLC now owns 7,620 shares of the medical equipment provider’s stock worth $681,000 after buying an additional 5,821 shares during the last quarter. CIBC Asset Management Inc increased its position in Boston Scientific by 4.4% in the 4th quarter. CIBC Asset Management Inc now owns 242,485 shares of the medical equipment provider’s stock valued at $21,659,000 after acquiring an additional 10,181 shares during the period. Finally, Highview Capital Management LLC DE raised its stake in Boston Scientific by 6.2% during the 4th quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider’s stock valued at $2,189,000 after acquiring an additional 1,439 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In related news, Director Edward J. Ludwig sold 4,877 shares of the business’s stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the sale, the director now directly owns 39,398 shares of the company’s stock, valued at $3,610,038.74. The trade was a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the transaction, the executive vice president now directly owns 5,502 shares in the company, valued at approximately $560,103.60. This represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 87,326 shares of company stock worth $8,673,948 in the last three months. 0.50% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms have recently issued reports on BSX. Wells Fargo & Company upped their price target on Boston Scientific from $100.00 to $118.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a research note on Friday, January 10th. Barclays raised their price objective on shares of Boston Scientific from $111.00 to $118.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Stifel Nicolaus boosted their target price on Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Thursday, February 6th. Finally, Morgan Stanley lifted their price target on Boston Scientific from $100.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. One equities research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Boston Scientific has an average rating of “Buy” and a consensus price target of $107.39.

Boston Scientific Stock Performance

NYSE:BSX opened at $106.20 on Tuesday. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The company has a market cap of $156.51 billion, a P/E ratio of 84.96, a P/E/G ratio of 2.79 and a beta of 0.80. The firm’s 50 day moving average is $96.44 and its two-hundred day moving average is $88.39. Boston Scientific Co. has a fifty-two week low of $65.33 and a fifty-two week high of $107.17.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. Analysts expect that Boston Scientific Co. will post 2.83 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.